Sickle cell disease: Clinical presentation and management of a global health challenge
on behalf of the SCORE Consortium
(2019) Blood Reviews, volume 37
(Article)
Abstract
Sickle cell disease is an autosomal recessive, multisystem disorder, characterised by chronic haemolytic anaemia, painful episodes of vaso-occlusion, progressive organ failure and a reduced life expectancy. Sickle cell disease is the most common monogenetic disease, with millions affected worldwide. In well-resourced countries, comprehensive care programs have increased life expectancy of
... read more
sickle cell disease patients, with almost all infants surviving into adulthood. Therapeutic options for sickle cell disease patients are however, still scarce. Predictors of sickle cell disease severity and a better understanding of pathophysiology and (epi)genetic modifiers are warranted and could lead to more precise management and treatment. This review provides an extensive summary of the pathophysiology and management of sickle cell disease and encompasses the characteristics, complications and current and future treatment options of the disease.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Complications, Sickle cell disease, Treatment, Vaso-occlusion, Hematology, Oncology, Journal Article, Review
ISSN: 0268-960X
Publisher: Churchill Livingstone
Note: Funding Information: Drs. M.E. Houwing, Dr. P.J. de Pagter, Dr. E. Nur, Drs. E. Rettenbacher, Dr. E.M. Schols, and Dr. R.Y.J. Tamminga have no conflicts of interest. Dr. E.J. van Beers has received grants from the Netherlands Organisation for Health Research and Development (ZonMw), Novartis, Agios, Bayer, RR Mechatronics, Novartis, Eurostars-2 Programme, the Dutch “Innovatiefonds Zorgverzekeraars” and National Institutes of Health. Prof. B.J. Biemond has received grants from the Netherlands Organisation for Health Research and Development (ZonMw), Fonds Nuts-Ohra, Janivo Stichting, the Egberts Stichting, and the NIH. Dr. A.W. Rijneveld is a member of Novartis honorarium for advisory board. Prof. J.N.J. Philipsen has received grants from the Netherlands Organisation for Health Research and Development (ZonMw), European Union 7th framework programme, and the Landsteiner Foundation for Blood Transfusion Research (LSBR). Prof. K. Fijn van draat has received grants from CSL Behring, Novo Nordisk and Bayer. Ass. Prof. M.H. Cnossen has received investigator-initiated research and travel grants from The Netherlands Organisation for Scientific Research (NWO)- the Netherlands Organisation for Health Research and Development (ZonMw), the Dutch “Innovatiefonds Zorgverzekeraars”, Pfizer, Bayer, Takedo, Novo Nordisk, Nordic Pharma, Novartis, CSL Behring, Sobi and Biogen Idec and is a member of the advisory boards of Bayer and Roche. Publisher Copyright: © 2019
(Peer reviewed)